Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
PD 0299685 at · 1 trial · 2 indications
| Arm | Type | Description |
|---|---|---|
| PD 0299685 15mg | EXPERIMENTAL | - |
| PD 0299685 30mg | EXPERIMENTAL | - |
| Placebo | PLACEBO_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| PD 0299685 at 15mg BID | DRUG | 5 mg Capsules, 3 to be taken in the morning and at bedtime for the duration of the study |
| PD 0299685 at 30mg BID | DRUG | 10mg Capsules, 3 to be taken in the morning and at bedtime for the duration of the study. Initial 2 week titration period at 15mg BID. |
| placebo for PD 0299685 | DRUG | Capsules identical in appearance to PD 0299685, 3 to be taken in the morning and at bedtime for the duration of the study |
Inclusion Criteria: * Men and women over 18 years of age with moderate to severe interstitial cystitis defined by pain score. * Women must not be pregnant or lactating, They may be post-menopausal, surgically sterilized or using an appropriate method of contraception. Exclusion Criteria: * Histor...
PD 0299685 is an investigational small molecule being studied for the treatment of symptoms associated with interstitial cystitis, also known as painful bladder syndrome. It is being developed by Pfizer, Inc. as a potential therapy for this urological condition.
The specific molecular target of PD 0299685 has not been disclosed in available information. It is a small molecule being investigated for its potential to treat symptoms of interstitial cystitis, but its mechanism of action has not been publicly detailed.
PD 0299685 is being developed by Pfizer, Inc., a pharmaceutical company listed on the New York Stock Exchange under the ticker symbol PFE. The company is conducting clinical research on this compound for interstitial cystitis.
PD 0299685 is in Phase 2 clinical development. It is an investigational drug, meaning it has not been approved by regulatory authorities and is still undergoing clinical trials to evaluate its safety and effectiveness for interstitial cystitis.
PD 0299685 has one completed Phase 2 clinical trial registered as NCT00739739. This randomized, double-blind, placebo-controlled study enrolled 161 participants with interstitial cystitis and painful bladder syndrome across the United States, Canada, Denmark, Finland, France, and Germany.
No alternative names for PD 0299685 have been disclosed in available information. It is identified solely by its development code PD 0299685 in clinical trial records and company communications.